Tag: REG

JACKSONVILLE, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency Centers” or the “Company”) (NASDAQ: REG) will announce its second quarter 2026 earnings results on Wednesday, July 29, 2026, after the market closes. The Company’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website – investors.regencycenters.com. The Company will host an earnings conference call on Thursday, July 30, 2026, at 11:00 a.m. ET.

Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development

RENO, Nev., June 08, 2026 (GLOBE NEWSWIRE) -- Ormat Technologies, Inc. (NYSE: ORA) (the “Company” or “Ormat”), a leading geothermal and renewable energy company and the only vertically integrated designer, builder, owner, and operator of geothermal facilities in the world, today announced the Ormega100, a revolutionary new surface power generation unit engineered to deliver higher output than any other binary solution currently on the market. The Ormega100 marks an accelerated opportunity to commercialize and scale its Enhanced Geothermal System (EGS) developments, connecting subsurface development with surface power generation at an accelerated pace.

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).